Speech treatment improves dysarthria in multisystemic ataxia: a rater-blinded, controlled pilot-study in ARSACS.


Journal

Journal of neurology
ISSN: 1432-1459
Titre abrégé: J Neurol
Pays: Germany
ID NLM: 0423161

Informations de publication

Date de publication:
May 2019
Historique:
received: 23 11 2018
accepted: 21 02 2019
revised: 14 02 2019
pubmed: 7 3 2019
medline: 14 8 2019
entrez: 7 3 2019
Statut: ppublish

Résumé

We aimed to provide proof-of-principle evidence that intensive home-based speech treatment can improve dysarthria in complex multisystemic degenerative ataxias, exemplified by autosomal recessive spastic ataxia Charlevoix-Saguenay (ARSACS). Feasibility and piloting efficacy of speech training specifically tailored to cerebellar dysarthria was examined through a 4-week program in seven patients with rater-blinded assessment of intelligibility (primary outcome) and naturalness and acoustic measures of speech (secondary outcomes) performed 4 weeks before, immediately prior to, and directly after training (intraindividual control design). Speech intelligibility and naturalness improved post treatment. This provides piloting evidence that ataxia-tailored speech treatment might be effective in degenerative cerebellar disease.

Identifiants

pubmed: 30840144
doi: 10.1007/s00415-019-09258-4
pii: 10.1007/s00415-019-09258-4
doi:

Types de publication

Journal Article Multicenter Study

Langues

eng

Pagination

1260-1266

Subventions

Organisme : National Health and Medical Research Council
ID : 1082910
Organisme : H2020 Excellent Science
ID : 643578
Organisme : BMBF
ID : 01GM1607

Références

J Speech Lang Hear Res. 2002 Jun;45(3):421-33
pubmed: 12068996
J Am Geriatr Soc. 2005 Apr;53(4):695-9
pubmed: 15817019
Neurology. 2006 Jun 13;66(11):1717-20
pubmed: 16769946
NeuroRehabilitation. 2008;23(3):207-16
pubmed: 18560137
J Voice. 2011 Mar;25(2):137-49
pubmed: 20171828
J Speech Lang Hear Res. 2010 Oct;53(5):1227-45
pubmed: 20798323
Int J Lang Commun Disord. 2011 Jan-Feb;46(1):1-16
pubmed: 21281410
Orphanet J Rare Dis. 2013 Mar 15;8:41
pubmed: 23497566
Clin Linguist Phon. 2013 Aug;27(8):647-60
pubmed: 23806133
J Speech Lang Hear Res. 2014 Jun 1;57(3):779-92
pubmed: 24687042
Cochrane Database Syst Rev. 2014 Oct 28;(10):CD008953
pubmed: 25348587
Am J Speech Lang Pathol. 2016 Feb;25(1):97-110
pubmed: 26882004
Mitochondrion. 2017 Nov;37:1-7
pubmed: 28634151
J Neurol. 2018 Sep;265(9):2060-2070
pubmed: 29968200
J Am Geriatr Soc. 1983 Dec;31(12):721-7
pubmed: 6418786
J Speech Hear Res. 1981 Sep;24(3):441-5
pubmed: 7300287

Auteurs

Adam P Vogel (AP)

Department of Neurodegeneration, Hertie Institute for Clinical Brain Research, Germany and Center for Neurology, University of Tübingen, University Hospital Tübingen, Tübingen, Germany. vogela@unimelb.edu.au.
Centre for Neuroscience of Speech, The University of Melbourne, 550 Swanston Street, Parkville, Melbourne, VIC, 3010, Australia. vogela@unimelb.edu.au.
RedenLab, Melbourne, Australia. vogela@unimelb.edu.au.

Lisa H Stoll (LH)

Department of Neurodegeneration, Hertie Institute for Clinical Brain Research, Germany and Center for Neurology, University of Tübingen, University Hospital Tübingen, Tübingen, Germany.
Therapiezentrum, University Hospital Tübingen, Tübingen, Germany.

Andreas Oettinger (A)

Neurology and Rehabilitation, Kliniken Schmieder, Gailingen am Hochrhein, Germany.

Natalie Rommel (N)

Department of Neurodegeneration, Hertie Institute for Clinical Brain Research, Germany and Center for Neurology, University of Tübingen, University Hospital Tübingen, Tübingen, Germany.
Therapiezentrum, University Hospital Tübingen, Tübingen, Germany.

Eva-Maria Kraus (EM)

Department of Neurodegeneration, Hertie Institute for Clinical Brain Research, Germany and Center for Neurology, University of Tübingen, University Hospital Tübingen, Tübingen, Germany.

Dagmar Timmann (D)

Department of Neurology, Essen University Hospital, University of Duisburg-Essen, Essen, Germany.

Dion Scott (D)

The University of Queensland, St Lucia, Australia.

Christina Atay (C)

The University of Queensland, St Lucia, Australia.

Elsdon Storey (E)

Department of Medicine, Monash University, Melbourne, Australia.

Ludger Schöls (L)

Department of Neurodegeneration, Hertie Institute for Clinical Brain Research, Germany and Center for Neurology, University of Tübingen, University Hospital Tübingen, Tübingen, Germany.
Center for Neurodegenerative Diseases (DZNE), Tübingen, Germany.

Matthis Synofzik (M)

Department of Neurodegeneration, Hertie Institute for Clinical Brain Research, Germany and Center for Neurology, University of Tübingen, University Hospital Tübingen, Tübingen, Germany.
Center for Neurodegenerative Diseases (DZNE), Tübingen, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH